Nivolumab for Melanoma, Non-small Cell Lung Cancer
Overview
Overview
Affiliations
Affiliations
Soon will be listed here.
References
1.
Borghaei H, Paz-Ares L, Horn L, Spigel D, Steins M, Ready N
. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015; 373(17):1627-39.
PMC: 5705936.
DOI: 10.1056/NEJMoa1507643.
View
2.
Gettinger S, Horn L, Gandhi L, Spigel D, Antonia S, Rizvi N
. Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2015; 33(18):2004-12.
PMC: 4672027.
DOI: 10.1200/JCO.2014.58.3708.
View
3.
Brahmer J, Drake C, Wollner I, Powderly J, Picus J, Sharfman W
. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010; 28(19):3167-75.
PMC: 4834717.
DOI: 10.1200/JCO.2009.26.7609.
View
4.
Atkinson V
. Medical management of malignant melanoma. Aust Prescr. 2015; 38(3):74-8.
PMC: 4653963.
DOI: 10.18773/austprescr.2015.028.
View
5.
Postow M, Chesney J, Pavlick A, Robert C, Grossmann K, McDermott D
. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015; 372(21):2006-17.
PMC: 5744258.
DOI: 10.1056/NEJMoa1414428.
View